302 related articles for article (PubMed ID: 16166198)
1. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression.
Brantley-Sieders DM; Fang WB; Hicks DJ; Zhuang G; Shyr Y; Chen J
FASEB J; 2005 Nov; 19(13):1884-6. PubMed ID: 16166198
[TBL] [Abstract][Full Text] [Related]
2. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation.
Brantley-Sieders DM; Caughron J; Hicks D; Pozzi A; Ruiz JC; Chen J
J Cell Sci; 2004 Apr; 117(Pt 10):2037-49. PubMed ID: 15054110
[TBL] [Abstract][Full Text] [Related]
3. Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice.
Brantley-Sieders DM; Fang WB; Hwang Y; Hicks D; Chen J
Cancer Res; 2006 Nov; 66(21):10315-24. PubMed ID: 17079451
[TBL] [Abstract][Full Text] [Related]
4. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.
Brantley DM; Cheng N; Thompson EJ; Lin Q; Brekken RA; Thorpe PE; Muraoka RS; Cerretti DP; Pozzi A; Jackson D; Lin C; Chen J
Oncogene; 2002 Oct; 21(46):7011-26. PubMed ID: 12370823
[TBL] [Abstract][Full Text] [Related]
5. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis.
Fang WB; Brantley-Sieders DM; Parker MA; Reith AD; Chen J
Oncogene; 2005 Nov; 24(53):7859-68. PubMed ID: 16103880
[TBL] [Abstract][Full Text] [Related]
6. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization.
Ogawa K; Pasqualini R; Lindberg RA; Kain R; Freeman AL; Pasquale EB
Oncogene; 2000 Dec; 19(52):6043-52. PubMed ID: 11146556
[TBL] [Abstract][Full Text] [Related]
7. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of EphA2 promotes tight junction formation and impairs angiogenesis in brain endothelial cells.
Zhou N; Zhao WD; Liu DX; Liang Y; Fang WG; Li B; Chen YH
Microvasc Res; 2011 Sep; 82(2):113-21. PubMed ID: 21726568
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
10. Vav3-rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence.
Lin KT; Gong J; Li CF; Jang TH; Chen WL; Chen HJ; Wang LH
Cancer Res; 2012 Jun; 72(12):3000-9. PubMed ID: 22659453
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of retinal neovascularization by soluble EphA2 receptor.
Chen J; Hicks D; Brantley-Sieders D; Cheng N; McCollum GW; Qi-Werdich X; Penn J
Exp Eye Res; 2006 Apr; 82(4):664-73. PubMed ID: 16359662
[TBL] [Abstract][Full Text] [Related]
12. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin.
Guo H; Miao H; Gerber L; Singh J; Denning MF; Gilliam AC; Wang B
Cancer Res; 2006 Jul; 66(14):7050-8. PubMed ID: 16849550
[TBL] [Abstract][Full Text] [Related]
13. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
[TBL] [Abstract][Full Text] [Related]
14. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.
Lu M; Miller KD; Gokmen-Polar Y; Jeng MH; Kinch MS
Cancer Res; 2003 Jun; 63(12):3425-9. PubMed ID: 12810680
[TBL] [Abstract][Full Text] [Related]
15. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Biochem Biophys Res Commun; 2004 Aug; 320(4):1096-102. PubMed ID: 15249202
[TBL] [Abstract][Full Text] [Related]
16. Inserting chromosome 18 into pancreatic cancer cells switches them to a dormant metastatic phenotype.
Lefter LP; Sunamura M; Furukawa T; Takeda K; Kotobuki N; Oshimura M; Matsuno S; Horii A
Clin Cancer Res; 2003 Oct; 9(13):5044-52. PubMed ID: 14581380
[TBL] [Abstract][Full Text] [Related]
17. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
18. A conditional feedback loop regulates Ras activity through EphA2.
Macrae M; Neve RM; Rodriguez-Viciana P; Haqq C; Yeh J; Chen C; Gray JW; McCormick F
Cancer Cell; 2005 Aug; 8(2):111-8. PubMed ID: 16098464
[TBL] [Abstract][Full Text] [Related]
19. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD
Breast Cancer Res Treat; 2011 Jun; 127(2):375-84. PubMed ID: 20602165
[TBL] [Abstract][Full Text] [Related]
20. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer.
Shin VY; Wu WK; Chu KM; Wong HP; Lam EK; Tai EK; Koo MW; Cho CH
Mol Cancer Res; 2005 Nov; 3(11):607-15. PubMed ID: 16317086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]